Discover
llllllllll JNJ-64304500 / J&JJNJ-64304500: NME filing in US for Crohn's disease between 2020-2023 (J&J) - Jul 16, 2020 - Pipeline Update: Regulatory submission in EU for Crohn's disease between 2020-2023[Screenshot]
llllllllll mirikizumab (LY3074828) / Eli LillyLUCENT-ACT: A Study of Mirikizumab (LY3074828) in Participants With Ulcerative Colitis (clinicaltrials.gov) - Jul 13, 2020 - P3b; N=1100; Not yet recruiting; Sponsor: Eli Lilly and Company
llllllllll mirikizumab (LY3074828) / Eli Lilly; Cosentyx (secukinumab) / NovartisLilly’s Mirikizumab Superior to Cosentyx (secukinumab) in a Phase 3 Study for Patients with Moderate to Severe Plaque Psoriasis (Eli Lilly Press Release) - Jul 17, 2020 - P3, N=1,443; OASIS-2 (NCT03535194); Sponsor: Eli Lilly and Company; "Eli Lilly and Company...announced today that mirikizumab...met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and all key secondary endpoints versus Cosentyx (secukinumab) at Week 16 (non-inferiority) and Week 52 (superiority) in the OASIS-2 study....'We are pleased with the positive results observed in the mirikizumab psoriasis development program (OASIS). Mirikizumab has the potential to be a meaningful treatment option for people living with psoriasis,' said Andrew Blauvelt, M.D....Lilly expects topline results for the Phase 3 induction data in ulcerative colitis in the spring of 2021 and for the Phase 3 Crohn's data in 2022; Lilly will submit data from OASIS-1 and 2 to regulatory authorities around the world."
llllllllll Tremfya (guselkumab) / J&JTremfya: Data from P2/3 GALAXI trial (NCT03466411) for Crohn’s disease in 2020 (J&J) - Jul 16, 2020 - Key 2020 Events[Screenshot]
llllllllll etrasimod (APD334) / ArenaELEVATE UC 12: Etrasimod Versus Placebo as Induction Therapy in Moderately to Severely Active Ulcerative Colitis (clinicaltrials.gov) - Jul 17, 2020 - P3; N=330; Recruiting; Sponsor: Arena Pharmaceuticals; Not yet recruiting --> Recruiting
llllllllll mirikizumab (LY3074828) / Eli LillyLily ’Mirikizumab’ approved for Phase 3 clinical trial for Crohn’s disease [Google Translation] (Medical News) - Jul 15, 2020 - "The Ministry of Food and Drug Safety (Chief Lee Eui-kyung) approved a phase 3 clinical trial to evaluate long-term efficacy and stability of 'Mirikizumab (LY3074828)' of 'Korea Lily' on the 13th....This phase 3 trial will be conducted at Ajou University Hospital, Inje University Haeundae Paik Hospital, Seoul Asan Hospital, Yeungnam University Hospital, and Gangbuk Samsung Hospital."
llllllllll Skyrizi (risankizumab) / AbbVie, Boehringer Ingelheim; Xeljanz (tofacitinib) / Pfizer, Marche Polytechnic University; Humira (adalimumab) / Eisai, AbbVie; Rinvoq (upadacitinib) / AbbViePharma's TV ad spending level sets in June, with AbbVie, Sanofi and Regeneron leading the way (Fierce Pharma) - Jul 16, 2020 - "The top 10 TV buyers' total spending was $141 million, almost the same as the $140 million from June 2019....Sanofi and Regeneron’s type 2 anti-inflammatory med Dupixent at $13.1 million in June TV media buys....1. Humira: Total estimated spending: $44.3 million (up from $32.5 million in May); 3. Xeljanz: Total estimated spending: $12.5 million (up from $11.5 million in May); 9. Rinvoq: Total estimated spending: $9 million (down from $12.9 million in May); 10. Skyrizi: Total estimated spending: $8.8 million (up from $8.7 million in May)."
